Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.

ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.

Gabrilovich D, Nefedova Y.

Cancer Cell. 2015 Aug 10;28(2):147-9. doi: 10.1016/j.ccell.2015.07.007.

2.

Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.

Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y.

Cancer Biol Ther. 2015;16(9):1422-6. doi: 10.1080/15384047.2015.1071743.

3.

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.

Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM, Nefedova Y.

PLoS One. 2015 Jan 30;10(1):e0117693. doi: 10.1371/journal.pone.0117693.

4.

Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis.

Liu H, Zhou J, Cheng P, Ramachandran I, Nefedova Y, Gabrilovich DI.

J Immunol. 2013 Aug 15;191(4):1916-26. doi: 10.4049/jimmunol.1300714.

5.

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D, Nefedova Y.

J Immunol. 2013 Apr 1;190(7):3815-23. doi: 10.4049/jimmunol.1203373.

6.

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.

Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI.

Nat Immunol. 2013 Mar;14(3):211-20. doi: 10.1038/ni.2526.

7.

Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y.

Cell Oncol (Dordr). 2011 Dec;34(6):545-51. doi: 10.1007/s13402-011-0060-6.

8.

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y.

Mol Cancer Ther. 2010 Dec;9(12):3200-9. doi: 10.1158/1535-7163.MCT-10-0372.

9.

Lipid accumulation and dendritic cell dysfunction in cancer.

Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI.

Nat Med. 2010 Aug;16(8):880-6. doi: 10.1038/nm.2172.

10.

Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Nefedova Y, Gabrilovich D.

Drug Resist Updat. 2008 Dec;11(6):210-8. doi: 10.1016/j.drup.2008.09.002. Review.

11.

Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands.

Cheng P, Nefedova Y, Corzo CA, Gabrilovich DI.

Blood. 2007 Jan 15;109(2):507-15.

13.

Activation of dendritic cells via inhibition of Jak2/STAT3 signaling.

Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, Gabrilovich DI.

J Immunol. 2005 Oct 1;175(7):4338-46.

Items per page

Supplemental Content

Loading ...
Support Center